Public record
Apixaban: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Label
FDA label facts for apixaban
The FDA label read for apixaban (Apixaban, application ANDA209810) was last revised on 2024-05-23. It carries a boxed warning. Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2024-05-23 | |
| Label read | Apixaban | ANDA209810, generic application |
| Boxed warning | Yes | |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient apixaban from an original manufacturer, not specific to Eliquis
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
Medicare Part D
Medicare Part D spending on apixaban
Medicare Part D spending on apixaban products was $20.77B in 2024 across 24,061,332 claims, compared with $18.27B in 2023 (+13.7%). Average spending per claim was $863, before rebates.
| Measure | Value |
|---|---|
| Total spending, 2024 | $20.77B |
| Total spending, 2023 | $18.27B |
| Change in spending, 2023 to 2024 | +13.7% |
| Claims (prescription fills), 2024 | 24,061,332 |
| Average spending per claim, 2024 | $863 |
How this was calculated
Summed total spending and claims over every brand and generic row with this generic name in the CMS file, using the Overall manufacturer rows. Combination products excluded. Average per claim is spending divided by claims.
Every single-ingredient apixaban product in Part D (Eliquis), 2024. Not limited to Eliquis.
Gross drug cost before manufacturer rebates, so net cost is lower. Part D excludes some uses by law (for example erectile dysfunction, weight loss and hair growth), so claims reflect covered uses only. Compounded products are not included.
Adverse event reports
Most reported events in FDA adverse event reports for apixaban
Through 2026-10-28, FDA had received 278,760 adverse event reports for apixaban, 209,860 of them marked serious by the reporter. The symptom terms named most often were dyspnoea (12,953), fatigue (12,481) and atrial fibrillation (10,893).
| Measure | Value | Note |
|---|---|---|
| All reports received | 278,760 | |
| Reports the reporter marked serious | 209,860 | death, hospitalisation, disability or similar outcome |
| Dyspnoea | 12,953 reports | |
| Fatigue | 12,481 reports | |
| Atrial fibrillation | 10,893 reports | |
| Diarrhoea | 10,197 reports | |
| Fall | 9,765 reports |
How this was calculated
Counted FAERS reports listing this active substance, then the reaction terms named most often. A report can name several reactions, and a term can describe the illness being treated and not an effect of the drug. Terms about product use or complaints rather than symptoms (for example death) were left out of the list.
Reports where FDA recorded apixaban as a single-ingredient active substance (any brand, not only Eliquis), all years to 2026-10-28
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs.